Treatment of ocular diseases
The present invention relates to the use of at least one protease for the manufacture of a medicament for the treatment and/or prevention of ocular diseases related to neoangiogenesis selected from the group consisting of age related macular degeneration (AMD), choroidal neovascularization, Hippel-Lindau Disease, iris neovascularization, ischemic proliferative retinopathy, neovascularization of the Cornea, and proliferative sickle cell retinopathy, wherein the at least one protease is selected from the group consisting of plant, non-mammalian animal and microbial proteases.
1. A method of treating ocular diseases related to neoangiogenesis comprising administering orally to an individual in need thereof, a therapeutically effective amount of at least bromelain and papain to reduce vascular endothelial growth factor (VEGF) induced tube formation related to ocular neoangiogenesis; wherein the ocular disease related to neoangiogenesis is selected from the group consisting of age related macular degeneration (AMD), choroidal neovascularisation, Hippel-Lindau Disease, iris neovascularisation, ischemic proliferative retinopathy, neovascularisation of the Cornea, and proliferative sickle cell retinopathy.
2. The method according to claim 1 , wherein the bromelain and papain are administered in a medicament in an amount from 10 to 90% w/w.
3. The method according to claim 1 , wherein the bromelain and papain are administered to an individual in an amount of 1 to 100 mg/kg body weight.
4. The method according to claim 1 , wherein the bromelain and papain are administered in a medicament comprising at least one pharmaceutical acceptable carrier, diluent and/or excipient.
5. The method according to claim 1 , wherein the bromelain and papain are administered in a tablet.
6. The method according to claim 1 , wherein the bromelain and papain are administered in a medicament comprising at least one further active ingredient.
7. The method according to claim 6 , wherein the at least one further active ingredient is a flavonoid and/or an antioxidant.
8. The method according to claim 7 , wherein the flavonoid is rutin.
9. The method according to claim 6 , wherein the further active ingredient is present in the medicament in an amount from 5 to 35% w/w.
10. The method according to claim 1 , wherein the bromelain and papain are administered in a medicament comprising optionally a further active ingredient.
11. The method according to claim 1 , wherein the bromelain and papain are administered in a medicament in an amount from 20 to 80% w/w.
12. The method according to claim 1 , wherein the bromelain and papain are administered in a medicament in an amount from 30 to 70% w/w.
13. The method according to claim 1 , wherein the bromelain and papain are administered to an individual in an amount of 2 to 50 mg/kg body weight.
14. The method according to claim 1 , wherein the bromelain and papain are administered to an individual in an amount of 5 to 20 mg/kg body weight.
15. The method according to claim 6 , wherein the further active ingredient is present in the medicament in an amount 10 to 30% w/w.
16. The method according to claim 6 , wherein the further active ingredient is present in the medicament in an amount from 15 to 25% w/w.
17. The method according to claim 1 , wherein the bromelain and papain are administered in a medicament comprising a binder, a filler, a disintegrant, a lubricant, a preservative and/or a coating.
18. The method according to claim 1 , wherein the bromelain and papain are administered in a medicament provided in a pharmaceutical form selected from the group consisting of soluble tablets, effervescent tablets, gastro-resistant tablets, sublingual tablets, and capsules.
19. The method according to claim 1 , wherein the bromelain and papain are administered in a medicament provided in a pharmaceutical form selected from the group consisting of gastro-resistant capsules, powders, granules, oral liquids, and oral drops.
20. The method according to claim 10 , wherein the further active ingredient is a flavonoid.
21. The method according to claim 20 , wherein the flavonoid is rutin.
22. A method of reducing vascular endothelial growth factor (VEGF) level in an individual with an increased risk of developing ocular disease related to neoangiogenesis comprising orally administering to the individual in need thereof, a composition comprising bromelain and papain in an effective amount to reduce VEGF level related to ocular neoangiogenesis; wherein the ocular disease related to neoangiogenesis is selected from the group consisting of age related macular degeneration (AMD), choroidal neovascularisation, Hippel-Lindau Disease, iris neovascularisation, ischemic proliferative retinopathy, neovascularisation of the Cornea, and proliferative sickle cell retinopathy.